https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29691 n = 39), rivaroxaban, (n = 56) or apixaban levels (n = 22) between February 2013 and November 2015 were analysed and compared to two different commercial drug specific calibrators from different manufacturers for each DOAC. Our results show that dabigatran (Hyphen and Technoclone) and rivaroxaban (Stago) calibrators tend to overestimate the APTT but are similar to patient samples for PT. A cut-off DOAC level of 50 ng/mL based on results from patient samples within the laboratory can be used as the lower limit which will result in prolongation of APTT for dabigatran (sensitivity 96%, n = 25) and PT for rivaroxaban (sensitivity 97%, n = 29), respectively. Individual laboratories should be familiar with the sensitivity of their coagulation reagents to different DOACs including differences between patient samples versus different commercial drug specific calibrators.]]> Wed 11 Apr 2018 15:02:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46031 NTR), are increasingly implicated in cancer progression, but their clinicopathological significance in oesophageal cancer is unclear. In this study, the expression of NGF, NTRK1 and NGFR were analysed by immunohistochemistry in a cohort of 303 oesophageal cancers versus 137 normal adjacent oesophageal tissues. Immunostaining was digitally quantified and compared to clinicopathological parameters. NGF and NGFR staining were found in epithelial cells and at similar levels between oesophageal cancers and normal oesophageal tissue. NGFR staining was slightly increased with grade (p=0.0389). Interestingly, NTRK1 staining was markedly higher in oesophageal squamous cell carcinoma (OR 2.31, 95%CI 1.13–4.38, p<0.0001) and significantly lower in adenocarcinoma (OR 0.50, 95%CI 0.44–0.63, p<0.0001) compared to normal oesophageal tissue. In addition, NTRK1 staining was decreased in grade 2 and grade 3 (OR 0.51, 95%CI 0.21–1.40, p<0.0001) compared to grade 1, suggesting a preferential involvement of this receptor in the more differentiated forms of oesophageal carcinomas. Together, these data point to NTRK1 as a biomarker and a candidate therapeutic target in oesophageal squamous cell carcinoma.]]> Wed 09 Nov 2022 15:59:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49047 1%. With results dichotomised as <1.0% or ≥1.0%, our proposed new method versus the ICSH method showed almost perfect agreement [observed agreement 95%, Cohen's kappa (κ)=0.84, SE 0.04, 95% CI 0.76–0.92, p<0.005]. Inter-observer strength of agreement for our method was moderate (Fleiss' κ for comparisons between three non-unique microscopists κ=0.50, SE 0.05, 95% CI 0.41–0.59, p<0.005). Intra-observer reproducibility assessed in two microscopists ranged from substantial (Cohen's κ=0.71, SE 0.08, 95% CI 0.55–0.86, p<0.005) to borderline almost perfect agreement (Cohen's κ=0.81, SE 0.07, 95% CI 0.68–0.93, p<0.005). Schistocyte quantitation using our new method is simpler than the 2012 ICSH method and had almost perfect agreement. Our finding of moderate inter-observer agreement in quantitating helmet, triangle and crescent schistocytes is applicable to both the ICSH and our newly proposed method. This finding underscores the importance of clinicopathological correlation and repeated examinations in the context of a clinically suspected TMA.]]> Wed 03 May 2023 15:40:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34224 Tue 19 Mar 2019 11:56:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34223 Tue 19 Mar 2019 11:49:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34222 Tue 19 Mar 2019 11:44:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34221 Tue 19 Mar 2019 11:41:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34205 Tue 19 Mar 2019 11:21:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17495 Tue 16 Jun 2015 15:41:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17482 Tue 16 Jun 2015 15:34:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51645 Tue 12 Sep 2023 20:16:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37661 Tue 09 Mar 2021 17:59:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31439 MLH1 promoter locus for dual MLH1/PMS2 negative tumours. On the basis of these results, genetic counselling and targeted germline mutation testing is then offered to patients considered at high risk of LS. From 1 August 2013 to 31 December 2015, 124 patients were screened (mean age 64.6 years). Thirty-six (29.0%) demonstrated abnormal MMR IHC: 26 (72.2%) showed dual loss of MLH1/PMS2, five (13.9%) dual loss of MSH2/MSH6, three (8.3%) isolated loss of MSH6, and two (5.6%) isolated loss of PMS2. Twenty-five of 26 (96.1%) patients with dual MLH1/PMS2 loss demonstrated MLH1 promoter methylation. Therefore, 11 (8.9%) patients screened were classified as high risk for LS, of whom nine (81.8%) accepted germline mutation testing. Three (2.4% of total screened) were confirmed to have LS, two with germline PMS2 and one with germline MSH2 mutation. Massive parallel sequencing of tumour tissue demonstrated somatic mutations which were concordant with the IHC results in the remainder. Interestingly, the one MLH1/PMS2 IHC negative but not hypermethylated tumour harboured only somatic MLH1 mutations, indicating that universal cascade methylation testing in MLH1/PMS2 IHC negative tumours is very low yield and could be reconsidered in a resource-poor setting. In conclusion, universal screening for LS in patients presenting with gynaecological malignancy using the algorithm described above identified LS in three of 124 (2.4%) of our population. Only three of nine (33.3%) patients considered at high risk for LS by combined IHC and hypermethylation analysis were proven to have LS. Only one of the LS patients was less than 50 years of age and none of these patients would have been identified had more restrictive Amsterdam or Bethesda criteria been applied.]]> Thu 27 Jan 2022 15:57:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29180 Thu 24 Mar 2022 11:30:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31062 Thu 17 Feb 2022 09:27:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40388 Thu 14 Jul 2022 11:42:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7929 Sat 24 Mar 2018 08:41:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15221 Sat 24 Mar 2018 08:26:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13301 Sat 24 Mar 2018 08:18:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10469 Sat 24 Mar 2018 08:09:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11165 Sat 24 Mar 2018 08:08:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4952 Sat 24 Mar 2018 07:48:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26599 Sat 24 Mar 2018 07:33:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24751 Clostridium difficile rose in prominence in the early 2000s with large-scale outbreaks of a particular binary toxin-positive strain, ribotype 027, in North America and Europe. In Australia outbreaks of the same scale had not and have not been seen. A survey of C. difficile across Australia was performed for 1 month in 2010. A collection of 330 C. difficile isolates from all States and Territories except Victoria and the Northern Territory was amassed. PCR ribotyping revealed a diverse array of strains. Ribotypes 014/020 (30.0%) and 002 (11.8%) were most common, followed by 054 (4.2%), 056 (3.9%), 070 (3.6%) and 005 (3.3%). The collection also contained few binary toxin positive strains, namely 027 (0.9%), 078 (0.3%), 244 (0.3%), 251 (0.3%) and 127 (0.3%). The survey highlights the need for vigilance for emerging strains in Australia, and gives an overview of the molecular epidemiology of C. difficile in Australia prior to an increase in incidence noted from mid-2011.]]> Sat 24 Mar 2018 07:14:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24769 Pathology.]]> Sat 24 Mar 2018 07:14:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41884 Mon 15 Aug 2022 15:25:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51900 Fri 22 Sep 2023 09:29:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47367 Fri 13 Jan 2023 14:57:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47360 Fri 13 Jan 2023 13:26:29 AEDT ]]>